医疗医药股受捧 春立/复锐/爱康/华领涨14%-17%
全球新冠疫潮未受控，近期多国更出现疫情反弹，且单日新增确诊宗数创纪录高，尤其是疫情肆虐的印度继昨天新增确诊病例超过31.4万宗新高後，今天新增确诊进一步急增逾33万宗，连续第二天打破美国所创单日确诊逾29.7万宗纪录，成为全球疫情爆发以来单日感染宗数最高国家，导致医疗系统濒临崩溃，日本多区周日起也会进入第三次紧急状态。另外，内地多只医疗医药股季绩理想，加上内地近期医美概念股受捧股价连日急涨，激发市场对医疗医药股热情。
本港相关股中，由复星医药(02196.HK)分拆上市的以色列医学美容器械制造商复锐医疗科技(01696.HK)升幅显着，该公司全资附属拟斥3.1亿人民币全购复星牙科，股价三连涨，午後高见9.62元，再创2017年9月上市以来新高，现造9.3元，急涨15%，成交续增至767万股。复星医药三连涨，今天股价高见39.95元，现造39.37元，续升逾3%。
获高盛升级至「买入」看14.91元的爱康医疗(01789.HK)升幅最大，股价重越百天线(12.3元)，最高见12.76元，现造12.5元，急涨17%，成交增至2,532万股。获高盛仍看14.4元的康基医疗(09997.HK)高见12.48元，现造12.16元，续升9%。
春立医疗(01858.HK)高见24.9元，创逾三个月高，现造24.55元，急涨14%，成交增至293万股。
华领医药-B(02552.HK)由低位连升第二天，今天股价重越10天、20天及50天线(4.23-4.7元)，最高见5.02元，现造4.95元，续涨17%，一向疏落的成交增至359万股。康宁杰瑞制药-B(09966.HK)三连涨，今天股价升破50天线(12.35元)，最高见13.02元，现造12.88元，续升6%。信达生物(01801.HK)六连升，今天股价高见90.25元，现造89.6元，续升3.8%。
蓝筹药明生物(02269.HK)高见115.4元，现造114.5元，续升3.9%；药明康德(02359.HK)反覆续升4.5%，报172元。亚盛医药-B(06855.HK)续升3%曾高见39.8元，创两个月高。
石药(01093.HK)续升3.3%报9.92元。威高股份(01066.HK)三连升，今天股价重越牛熊线(15.77元)，最高见16.72元，现造16.58元，续升6.5%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
